Global Treatment-resistant Depression Treatment Market Size study & Forecast, by Drug Type (NMDA, Antidepressants, Antipsychotics, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and Regional Anal

Global Treatment-resistant Depression Treatment Market Size study & Forecast, by Drug Type (NMDA, Antidepressants, Antipsychotics, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2022-2029

Global Treatment-resistant Depression Treatment Market is valued at approximately USD 1.52 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.0% over the forecast period 2022-2029. Treatment-Resistant Depression (TRD) is a variety of Major Depressive Disorder (MDD) that cause due to the improper response of at least two antidepressants in the treatment process. The inflammatory system activation, neurotransmitter dysfunction, abnormal neural activity, melancholic clinical features, bipolarity, and a higher traumatic load are some conditions that are associated with this disorder. The rising inclination towards other routes of administration compared to oral administration, the increasing drug development projects, and increasing healthcare expenditure are some primary factors that are propelling the market demand across the globe.

The rise in the prevalence of this mood disorder is a key factor that is contributing to the market's growth. TRD occurs when a person hasn't reacted to two separate antidepressant doses taken for a sufficient amount of time, typically six weeks. The demand for the treatment of treatment-resistant depression has increased as a result of the rise in the prevalence of this medical disease. Springer reported that in August 2021, there are more than 300 million individuals worldwide suffer from significant depressive disorders, and over one-third of those people have depression that is treatment-resistant depression. Hence, the rising disease burden is a catalyzing factor for the market's growth. Moreover, rising investment in research and development activities, as well as the increasing initiatives by the key market players are presenting various lucrative opportunities over the forecasting years. However, the limited therapeutic measure and lack of clarity in guidelines for diagnosis and management of this mood disorder patients are restricting the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Treatment-resistant Depression Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing number of guidelines and approval of drugs, along with the significant R&D investment and increasing focus of market players. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing patient population suffering from treatment-resistant depressive disorder, as well as increasing awareness related to the treatment of mood disorder in the market space.

Major market players included in this report are:
Eli Lilly and Company
GlaxoSmithKline Plc
Pfizer Inc.
Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
AbbVie Inc.
AstraZeneca Plc
H. Lundbeck A/S
Sandoz International GmbH (Novartis AG)
Par Pharmaceutical (Endo International plc)
Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Recent Developments in the Market:
 In August 2022, Merck Sharp & Dohme LLC initiated the clinical trial of its Phase IIa to evaluate the efficacy and safety of the company’s MK-1942 among treatment-resistant depression patients.
 In July 2022, Novartis Pharmaceuticals declared that the company is planning to initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.


Global Treatment-resistant Depression Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Drug Type:
NMDA
Antidepressants
Antipsychotics
Others
By Distribution Channel:
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World





Companies Mentioned

Eli Lilly and Company
GlaxoSmithKline Plc
Pfizer Inc.
Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
AbbVie Inc.
AstraZeneca Plc
H. Lundbeck A/S
Sandoz International GmbH (Novartis AG)
Par Pharmaceutical (Endo International plc)
Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.


Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Treatment-resistant Depression Treatment Market, by Region, 2019-2029 (USD Billion)
1.2.2. Treatment-resistant Depression Treatment Market, by Drug Type, 2019-2029 (USD Billion)
1.2.3. Treatment-resistant Depression Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Treatment-resistant Depression Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Treatment-resistant Depression Treatment Market Dynamics
3.1. Treatment-resistant Depression Treatment Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rise in the prevalence of treatment-resistant depression
3.1.1.2. Increasing drug development projects
3.1.2. Market Challenges
3.1.2.1. Limited therapeutic measure
3.1.2.2. Lack of clarity in guidelines for diagnosis and management of this mood disorder patients
3.1.3. Market Opportunities
3.1.3.1. Rising investment in research and development activities
3.1.3.2. Increasing initiatives by the key market players
Chapter 4. Global Treatment-resistant Depression Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Treatment-resistant Depression Treatment Market, by Drug Type
6.1. Market Snapshot
6.2. Global Treatment-resistant Depression Treatment Market by Drug Type, Performance - Potential Analysis
6.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
6.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
6.4.1. NMDA
6.4.2. Antidepressants
6.4.3. Antipsychotics
6.4.4. Others
Chapter 7. Global Treatment-resistant Depression Treatment Market, by Distribution Channel
7.1. Market Snapshot
7.2. Global Treatment-resistant Depression Treatment Market by Distribution Channel, Performance - Potential Analysis
7.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
7.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
7.4.1. Hospital Pharmacies
7.4.2. Drug Stores & Retail Pharmacies
7.4.3. Online Pharmacies
Chapter 8. Global Treatment-resistant Depression Treatment Market, Regional Analysis
8.1. Treatment-resistant Depression Treatment Market, Regional Market Snapshot
8.2. North America Treatment-resistant Depression Treatment Market
8.2.1. U.S. Treatment-resistant Depression Treatment Market
8.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Treatment-resistant Depression Treatment Market
8.3. Europe Treatment-resistant Depression Treatment Market Snapshot
8.3.1. U.K. Treatment-resistant Depression Treatment Market
8.3.2. Germany Treatment-resistant Depression Treatment Market
8.3.3. France Treatment-resistant Depression Treatment Market
8.3.4. Spain Treatment-resistant Depression Treatment Market
8.3.5. Italy Treatment-resistant Depression Treatment Market
8.3.6. Rest of Europe Treatment-resistant Depression Treatment Market
8.4. Asia-Pacific Treatment-resistant Depression Treatment Market Snapshot
8.4.1. China Treatment-resistant Depression Treatment Market
8.4.2. India Treatment-resistant Depression Treatment Market
8.4.3. Japan Treatment-resistant Depression Treatment Market
8.4.4. Australia Treatment-resistant Depression Treatment Market
8.4.5. South Korea Treatment-resistant Depression Treatment Market
8.4.6. Rest of Asia Pacific Treatment-resistant Depression Treatment Market
8.5. Latin America Treatment-resistant Depression Treatment Market Snapshot
8.5.1. Brazil Treatment-resistant Depression Treatment Market
8.5.2. Mexico Treatment-resistant Depression Treatment Market
8.5.3. Rest of Latin America Treatment-resistant Depression Treatment Market
8.6. Rest of The World Treatment-resistant Depression Treatment Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Eli Lilly and Company
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. GlaxoSmithKline Plc
9.2.3. Pfizer Inc.
9.2.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
9.2.5. AbbVie Inc.
9.2.6. AstraZeneca Plc
9.2.7. H. Lundbeck A/S
9.2.8. Sandoz International GmbH (Novartis AG)
9.2.9. Par Pharmaceutical (Endo International plc)
9.2.10. Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
List of Tables
TABLE 1. Global Treatment-resistant Depression Treatment Market, report scope
TABLE 2. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
TABLE 3. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
TABLE 4. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
TABLE 5. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 6. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 7. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 8. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 9. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 10. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 11. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 12. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 13. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 14. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 15. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 16. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 17. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 18. Canada Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 19. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 20. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 21. UK Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 22. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 23. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 24. Germany Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 25. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 26. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 27. France Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 28. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 29. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 30. Italy Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 31. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 32. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 33. Spain Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 34. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 35. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 36. RoE Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 37. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 38. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 39. China Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 40. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 41. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 42. India Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 43. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 44. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 45. Japan Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 46. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 47. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 48. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 49. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 50. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 51. Australia Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 52. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 53. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 54. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 55. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 56. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 57. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 58. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 59. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 60. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 61. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 62. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 63. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 64. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 65. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 66. Row Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 67. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 68. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Treatment-resistant Depression Treatment Market
TABLE 70. List of primary sources, used in the study of global Treatment-resistant Depression Treatment Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
FIG 1. Global Treatment-resistant Depression Treatment Market, research methodology
FIG 2. Global Treatment-resistant Depression Treatment Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Treatment-resistant Depression Treatment Market, key trends 2021
FIG 5. Global Treatment-resistant Depression Treatment Market, growth prospects 2022-2029
FIG 6. Global Treatment-resistant Depression Treatment Market, porters 5 force model
FIG 7. Global Treatment-resistant Depression Treatment Market, pest analysis
FIG 8. Global Treatment-resistant Depression Treatment Market, value chain analysis
FIG 9. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
FIG 10. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
FIG 11. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
FIG 12. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
FIG 13. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
FIG 14. Global Treatment-resistant Depression Treatment Market, regional snapshot 2019 & 2029
FIG 15. North America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
FIG 16. Europe Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
FIG 17. Asia pacific Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
FIG 18. Latin America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
FIG 19. Global Treatment-resistant Depression Treatment Market, company Market share analysis (2021)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings